Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer

Fig. 3

LXY30 specifically binds to live, circulating tumor cells in patient’s malignant pleural effusion. Representative tumor cells isolated from malignant pleural effusion from a patient with lung adenocarcinoma using Ficoll-Paque gradient separation bound to LXY30-coated but not S-LXY30-coated TentaGel beads after 2 h incubation (a, left panel). PBMCs isolated from the same patients did not bind to LXY30-coated or S-LXY30-coated beads (a, right panel). Flow cytometry confirmed that LXY30 specifically bound to tumor cells in malignant pleural effusion but not the PBMCs isolated from the same patient (b). Tumor cells from malignant pleural effusion of a newly diagnosed lung cancer patient cells were subjected to a serial dilution (1:103) using 1 mL of supernatant, followed by incubation with ~ 250 TentaGel beads coated with LXY30 or S-LXY30 for 2 h. Representative images were visualized by microscope (× 10) (c). Arrow in red points to the individual live, bound tumor cells on the beads. On average, LXY30 enriched tumor cells by ~ 2-fold (d). Representative images showing tumor cells from malignant pleural effusion of a newly diagnosed lung cancer patient were visualized by light microscope (e). Red arrows point to the individual live tumor cells bound on the LXY30 beads (upper panel) but not S-LXY30 beads (lower panel). PBMC, pleural blood mononuclear cell

Back to article page